Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $34.50.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, March 4th.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CAPR. Oppenheimer & Co. Inc. grew its position in Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after acquiring an additional 13,762 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics during the third quarter valued at about $161,000. FMR LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter worth about $370,000. BNP Paribas Financial Markets boosted its position in shares of Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after buying an additional 15,872 shares during the period. Finally, Fred Alger Management LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter worth about $399,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 3.4 %

Shares of NASDAQ:CAPR opened at $13.23 on Tuesday. The company has a market cap of $601.57 million, a P/E ratio of -12.48 and a beta of 4.10. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The business has a fifty day simple moving average of $14.18 and a 200-day simple moving average of $14.34.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.